Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.

Dengler MA, Teh CE, Thijssen R, Gangoda L, Lan P, Herold MJ, Gray DH, Kelly GL, Roberts AW, Adams JM.

Oncogene. 2019 Nov 26. doi: 10.1038/s41388-019-1122-x. [Epub ahead of print]

PMID:
31772331
2.

Characterization of a novel human BFL-1-specific monoclonal antibody.

Gangoda L, Teh CE, Dengler MA, Best SA, Weeden CE, Tai L, Lee EF, Fairlie WD, Sutherland KD, Harrison LC, Gray DH, Strasser A, Herold MJ.

Cell Death Differ. 2019 Nov 12. doi: 10.1038/s41418-019-0454-y. [Epub ahead of print] No abstract available.

PMID:
31719651
3.

Deletion of self-reactive CCR7- thymocytes in the absence of MHC expression on thymic epithelial cells.

Wirasinha RC, Chan A, Yap JY, Hu DY, Teh CE, Gray DHD, Goodnow CC, Daley SR.

Cell Death Differ. 2019 Dec;26(12):2727-2739. doi: 10.1038/s41418-019-0331-8. Epub 2019 Apr 24.

PMID:
31019259
4.

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ.

Cancer Discov. 2019 Mar;9(3):354-369. doi: 10.1158/2159-8290.CD-18-1151. Epub 2018 Dec 5.

PMID:
30518523
5.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
6.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
7.

Characterization of Blimp-1 function in effector regulatory T cells.

Cretney E, Leung PS, Trezise S, Newman DM, Rankin LC, Teh CE, Putoczki TL, Gray DH, Belz GT, Mielke LA, Dias S, Nutt SL.

J Autoimmun. 2018 Jul;91:73-82. doi: 10.1016/j.jaut.2018.04.003. Epub 2018 Apr 30.

PMID:
29724515
8.

The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, Strasser A.

Cell Death Differ. 2017 Dec;24(12):2032-2043. doi: 10.1038/cdd.2017.125. Epub 2017 Aug 11.

9.

Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment.

Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE, Gray DH, Tai L, Lew AM, Villunger A, Strasser A, Herold MJ.

Cell Death Differ. 2017 Mar;24(3):534-545. doi: 10.1038/cdd.2016.156. Epub 2017 Jan 13.

10.

Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis.

Teh CE, Lalaoui N, Jain R, Policheni AN, Heinlein M, Alvarez-Diaz S, Sheridan JM, Rieser E, Deuser S, Darding M, Koay HF, Hu Y, Kupresanin F, O'Reilly LA, Godfrey DI, Smyth GK, Bouillet P, Strasser A, Walczak H, Silke J, Gray DH.

Nat Commun. 2016 Nov 18;7:13353. doi: 10.1038/ncomms13353.

11.

Can you rely on Treg cells on the rebound?

Teh CE, Gray DH.

Eur J Immunol. 2014 Dec;44(12):3504-7. doi: 10.1002/eji.201445273. Review.

12.

Heterozygous mis-sense mutations in Prkcb as a critical determinant of anti-polysaccharide antibody formation.

Teh CE, Horikawa K, Arnold CN, Beutler B, Kucharska EM, Vinuesa CG, Bertram EM, Goodnow CC, Enders A.

Genes Immun. 2013 Jun;14(4):223-33. doi: 10.1038/gene.2013.11. Epub 2013 Apr 4.

13.

B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8- dendritic cells require the intramembrane endopeptidase SPPL2A.

Bergmann H, Yabas M, Short A, Miosge L, Barthel N, Teh CE, Roots CM, Bull KR, Jeelall Y, Horikawa K, Whittle B, Balakishnan B, Sjollema G, Bertram EM, Mackay F, Rimmer AJ, Cornall RJ, Field MA, Andrews TD, Goodnow CC, Enders A.

J Exp Med. 2013 Jan 14;210(1):31-40. doi: 10.1084/jem.20121076. Epub 2012 Dec 24.

14.

Anti-islet autoantibodies trigger autoimmune diabetes in the presence of an increased frequency of islet-reactive CD4 T cells.

Silva DG, Daley SR, Hogan J, Lee SK, Teh CE, Hu DY, Lam KP, Goodnow CC, Vinuesa CG.

Diabetes. 2011 Aug;60(8):2102-11. doi: 10.2337/db10-1344.

15.

ATP11C is critical for the internalization of phosphatidylserine and differentiation of B lymphocytes.

Yabas M, Teh CE, Frankenreiter S, Lal D, Roots CM, Whittle B, Andrews DT, Zhang Y, Teoh NC, Sprent J, Tze LE, Kucharska EM, Kofler J, Farell GC, Bröer S, Goodnow CC, Enders A.

Nat Immunol. 2011 May;12(5):441-9. doi: 10.1038/ni.2011. Epub 2011 Mar 20.

16.

T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.

Teh CE, Daley SR, Enders A, Goodnow CC.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14709-14. doi: 10.1073/pnas.1009209107. Epub 2010 Jul 28.

17.

The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells.

Wang J, Lee S, Teh CE, Bunting K, Ma L, Shannon MF.

Int Immunol. 2009 Mar;21(3):227-35. doi: 10.1093/intimm/dxn143. Epub 2009 Jan 30.

PMID:
19181930

Supplemental Content

Support Center